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Abstract: Standard depression treatments, including antidepressant medication and cognitive 
behavioural therapy (CBT) are ineffective for many patients. Prefrontal transcranial direct 
current stimulation (tDCS) has shown inconsistent efficacy as an experimental treatment for 
depression, and its mechanisms are poorly understood. We recruited unmedicated patients with 
major depressive disorder (N=71 approached; N=39 randomised) for a mechanistic, double-
blind, randomized controlled trial consisting of eight weekly sessions of prefrontal tDCS 
administered to the left prefrontal cortex prior to CBT. We probed (1) whether tDCS improved 
the efficacy of CBT relative to sham stimulation; and (2) whether neural measures predicted 
clinical response. We found a modest and non-significant effect of tDCS on clinical outcome 
over-and-above CBT (active: 50%; sham: 31.6%; odds ratio: 2.16, 95%CI=0.59—7.99),but a 
strong relationship, predicted a priori, between baseline activation in the stimulated prefrontal 
region and symptom improvement. Repeating our analyses of symptom outcome splitting the 
sample according to this biomarker revealed that tDCS was significantly superior to sham in 
individuals with high L-DLPFC activation at baseline; we also show 86% accuracy in predicting 
clinical response using this measure. Exploratory analyses revealed several other regions where 
activation at baseline was associated with subsequent response to CBT, irrespective of tDCS. 
This mechanistic trial revealed variable, but predictable, clinical effects of prefrontal tDCS 
combined with CBT for depression. We have discovered a potential explanation for this 
variability: individual differences in baseline activation of the region stimulated. Such a 
biomarker could potentially be used to pre-select patients for trials and, eventually, in the clinic. 
 
Trial Registration: The trial was registered at clinicatrials.gov, registration number 
NCT01875419; URL: 
https://clinicaltrials.gov/ct2/show/NCT01875419?term=NCT01875419&rank=1 
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Introduction 
 
Cognitive behavioural therapy (CBT) is a common, effective treatment for depression[1]. 
Nevertheless, only 60% of patients show an adequate response to therapy; even fewer achieve 
remission[2]. Some researchers have suggested improving CBT response with augmentative 
strategies, such as cognitive-enhancing drugs[3]. More recently, noninvasive brain stimulation, 
including repetitive transcranial magnetic stimulation (rTMS)[4] and transcranial direct current 
stimulation (tDCS)[5], has been suggested as a strategy to enhance response to CBT.  
     
Both rTMS and tDCS have been applied as treatments for depression over the dorsolateral 
prefrontal cortex (DLPFC), a region disrupted in both currently-depressed[6] and remitted 
patients[7,8]. Stimulation of the DLPFC directly affects its activation, as well that of distal 
regions including the cingulate cortex[9,10]. Previous trials have shown that prefrontal tDCS has 
a moderately strong antidepressant effect[11–16]. 
 
Recently, a large multi-centre trial failed to show any evidence in support of tDCS, even finding 
a potentially detrimental effect for unipolar depression[17]. This inconsistency echoes non-
clinical experiments. Initially, many results suggested that prefrontal tDCS enhances cognitive 
performance, including planning[18], insight [19], and cognitive control during and after tDCS, 
in both healthy[20,21] and depressed[22] individuals. However, the cognitive effects of tDCS 
also appear highly variable [21,23,24]; a quantitative review suggested there were no consistent 
effect of tDCS on any cognitive process in healthy individuals[23] (for a critique of this review, 
see[25]).  
 
If prefrontal tDCS improves cognitive control, it may improve patients‘ ability to benefit from 
CBT, which itself entails challenging cognitive processing, including planning and working 
memory[1]. This is supported by preliminary evidence that tDCS enhances the antidepressant 
effects of cognitive control training[26] and, in a small feasibility trial (N=10), internet-based 
CBT[27]. However, given the inconsistent evidence for tDCS in both cognition[23] and 
depression[17], it is also likely there are substantial individual differences in response to tDCS-
enhanced CBT.  
 
A key priority for psychiatric research is identifying objective measures to help optimize 
treatment selection[28]. There is preliminary evidence that pre-treatment neural activation 
(measured with functional magnetic resonance imaging: fMRI) can predict response to 
antidepressant medication and CBT[29]. However, studies investigating such associations 
invariably lack comparison groups and randomization to groups. To identify biomarkers 
unambiguously, mechanistic measurements need to be incorporated into randomized controlled 
trials (RCTs). 
 
A strong candidate biomarker for response to noninvasive brain stimulation in depression is 
activation of the region stimulated (usually the DLPFC): experimentalists have hypothesized that 
baseline DLPFC activity might mediate the cognitive effects of prefrontal tDCS on 
cognition[24]; and one small study in depressed patients reported that higher pre-treatment 
DLPFC resting-state perfusion was associated with better clinical response to DLPFC rTMS[30].  
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Therefore we conducted a mechanistic, proof-of-principle RCT of prefrontal tDCS to augment 
CBT in unmedicated patients with unipolar depression. We hoped to capitalise on the sustained 
(~90 minute) aftereffects of tDCS on cortical excitability by delivering stimulation immediately 
prior to weekly CBT sessions[31]. Our study had two key aims: 1) to assess whether tDCS 
augments the ability of CBT to treat depression over and above sham (placebo) stimulation; and 
2) to explore putative pre-treatment biomarkers. We also aimed to identify the cognitive and 
neural changes resulting from combined CBT and tDCS. We hypothesized that 1) tDCS would 
improve response to CBT; and 2) that higher pre-treatment activation in the DLPFC would 
predict better response to combined CBT and tDCS.  
 
Materials and Methods 
Participants 
 
We randomized 39 unmedicated patients with major depressive disorder (Hamilton Rating Scale 
for Depression (HAM-D)>17) to receive real (N=20) or sham (N=19) tDCS. Patients were 
recruited through the Camden and Islington NHS Foundation Trust Improving Access to 
Psychological Treatment (IAPT) service within the UK National Health Service (NHS). Patients, 
investigators, and therapists were blind to tDCS condition for the duration of the trial. Six 
patients did not complete the intervention (defined as ≥7/8 sessions: 1 active; 5 sham); dropout 
rates differed marginally (non-significantly) between groups (p=0.091)); to account for potential 
non-random dropout we employed intention-to-treat analyses as our primary analysis. Thirty-one 
patients received eight sessions of CBT and two patients received seven sessions of CBT. See 
Figure 1 for CONSORT diagram and procedure.  
 
Only patients meeting criteria for at least moderate depression where the IAPT service assigned 
one-on-one cognitive behavioural therapy (CBT) for depression were included in the trial (see 
Supplemental Materials for full participant criteria). The study was approved by the London 
Queen Square NHS Research Ethics Committee (ID: 13/LO/1028); subjects‘ consent was 
obtained in accordance with the Declaration of Helsinki. 
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Fig 1. CONSORT diagram describing recruitment, randomization, and attrition in the clinical trial (A) 
and depiction of trial procedure (B). CBT=cognitive behavioural therapy; tDCS=transcranial direct 
current stimulation; HAM-D=Hamilton Rating Scale for Depression; fMRI=functional magnetic 
resonance imaging. 
Protocol 
 
The study protocol was registered on clinicaltrials.gov (NCT01875419). See Figure 1A for 
CONSORT diagram. See Figure 1B for trial protocol, consisting of a screening session, fMRI 
scans (before and after intervention), and randomization (using custom-written MATLAB code 
by a researcher not involved in the trial). See Supplemental Materials for the full protocol.  
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6 
 
Imaging details 
The MRI protocol included a T1-weighted anatomical scan and two T2*-weighted functional 
scans (n-back working memory task [21], practiced at the screening session to ensure 
participants could perform the task; and an emotion processing task [32] where participants 
discriminated the gender of fearful, happy, and neutral faces). See Supplemental Materials for 
full details. 
Stimulation procedure 
Immediately preceding each CBT session, a 1mA constant current fronto-extracephalic montage 
was delivered to the left prefrontal cortex (anode on F3 on the international 10-20 
electroencephalography (EEG) system (using an EEG cap for placement), secured in place with 
an elasticated head-strap; cathode on ipsilateral deltoid). Although this delivers relatively diffuse 
prefrontal stimulation[33]), an open-label, preliminary study comparing bifrontal and fronto-
extracephalic tDCS in depression found that frontoextracephalic tDCS was more effective[34]  
motivating our choice (note, however, that this study may have been underpowered: N=11). We 
were restricted to 1mA by our ethics committee; however, a recent study found that only 
unilateral 1mA stimulation (and not bilateral 1mA or 2mA) caused sustained increases in 
corticospinal excitability[35].  
 
The stimulation, delivered using a neuroConn DC-stimulator, lasted for 20 minutes. Sham 
stimulation involved 30 seconds of direct current followed by 1,170 seconds without, which 
produces a similar sensation to active stimulation (most sensations are felt in the first 30 seconds 
during ramping up), resulting in effective blinding at 1mA[36]. Both electrodes were 35 cm
2 
(7 
cm x 5 cm), rubber, and placed inside electrode sponges that had been briefly soaked in saline to 
conduct the current. The polarity of the device was independently verified using a resistor and 
volt-meter. For practicality, tDCS was administered prior to CBT. Following stimulation, 
patients completed the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and 
Snaith-Hamilton Pleasure Scale (SHAPS).  
 
Patients performed the n-back working memory task during stimulation (in real and sham 
stimulation conditions), as previous studies reported enhanced cognitive effects of tDCS when 
delivered concurrently with a working memory paradigm[26]. The n-back task was identical to 
the version patients were previously trained on and performed inside the scanner. 
Therapy procedure 
 
Immediately following each tDCS session, patients received a one-hour CBT intervention for 
depression, as described previously[37]. Sessions occurred a minimum of six days apart.  
We decreased variability in CBT delivery by working with a selected team of therapists, 
doctoral-level clinical psychologists working in the NHS IAPT service, which itself has 
standardised training and CBT delivery. To ensure adherence to protocol, therapists also received 
regular supervision of CBT sessions by supervisors accredited by the British Association of 
Behavioural and Cognitive Psychotherapists (BABCP). To increase consistency of CBT, we ran 
a day-long expert-led training for all therapists before recruitment.  
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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Side effects and blinding 
 
At each session, following tDCS, patients filled out the tDCS Adverse Events Questionnaire 
[38], and guessed their stimulation condition. At four sessions, the Adverse Events questionnaire 
was not completed due to time constraints. 
 
Analyses 
 
Our primary clinical outcome measure was response rate according to the HAM-D, defined as a 
reduction of at least 50% from baseline; we also report remission rate, defined as a HAM-D 
score of 7 or below. We analysed our primary outcome with an intent-to-treat analysis 
(accounting for missing values at follow-up using last-observation-carried-forward: N=39) as we 
could not assume attrition occurred completely at random. We analysed secondary outcome 
measures (BDI, BAI, SHAPS, and working memory performance d’ (previously described [21])) 
with linear mixed models, which accounts for missing data by estimating the trajectory of change 
for the subjects who did provide data (see Supplemental Materials for details).  
 
For all measures, we repeated this analysis using the sample of patients who completed the 
treatment.  
 
fMRI analyses (on sample who completed) were performed in SPM12 
(https://www.fil.ion.ucl.ac.uk/spm/). Our primary analyses used regions of interest (ROIs): left 
and right amygdala. subgenual anterior cingulate cortex, and L-DLPFC defined anatomically 
(emotion processing task; contrasts: fearful>neutral faces and happy>neutral faces); and R-and 
L-DLPFC (n-back task). L-DLPFC was identified by placing a 10mm sphere on coordinates 
from a meta-analysis of working memory tasks, the majority of which used the n-back (-
44,20,30)[6]; R-DLPFC was defined using the corresponding contralateral coordinate (44,20,30). 
We additionally conducted an exploratory whole-brain flexible factorial analysis (with an initial 
cluster-forming threshold of p<0.001, uncorrected). For these exploratory analyses, we use a 
Bonferroni-corrected significance threshold of p=0.025 (FWE-corrected), reporting significance 
at the cluster- or voxel-level. 
Outcome prediction analysis 
 
We first mean-corrected all predictor variables: R- and L-DLPFC activation; R- and L-amygdala 
activation; sgACC activation; n-back d’; SHAPS; BAI; and HAM-D. Note all predictor variables 
were acquired prior to randomisation. 
 
Our primary analyses tested whether pre-randomization activation averaged within each ROI 
(the L-DLPFC for the n-back task; the amygdalae and sgACC for the emotional faces task; all 
analysed in separate regressions) could predict the degree of clinical improvement (HAM-D 
percent change). Each regression also included the fixed effect of stimulation condition and the 
interaction between stimulation condition and baseline ROI activation. If this model was 
significant, we then conducted sensitivity analyses that tested whether the prediction remained 
significant following inclusion of additional variables in the model (HAM-D, BAI, and SHAPS 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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scores, as well as n-back performance, and their interactions with stimulation group) (see 
Supplemental Materials for details). 
Power calculation 
 
This was a mechanistic, proof-of-principle trial powered to detect a large effect size, as reported 
in a previous trial of tDCS in antidepressant-free patients (Hedges‘ g=0.988)[11] and report of 
tDCS enhancing n-back performance (Cohen‘s d=1.42)[21]. We had 80% power to detect 
w=0.45 (X
2
 test; alpha=0.05) for our primary clinical outcome variable (HAM-D), which was 
binary. For continuous variables, including our mechanistic (fMRI) measures, we had 80% 
power to detect d=1.0 (independent samples t-test; alpha=0.05 (two-tailed)). 
  
©    2019 American College of Neuropsychopharmacology. All rights reserved.
9 
 
 
Results  
Clinical and demographic data are presented in Table 1. There were no differences in baseline 
generalised anxiety disorder (GAD) between patients subsequently assigned to real and sham 
conditions: 14/20 patients assigned to real stimulation, and 13/19 patients assigned to sham 
stimulation, met criteria for GAD (X
2
=0.011, p=0.915). 
 
Table 1. Participant characteristics by stimulation condition. 
Other than N and percentage data, figures represent means (standard deviations); FSIQ = Full Scale Intelligence 
Quotient (calculated from Weschler Test of Adult Reading); HAM-D = Hamilton Rating Scale for Depression; BDI 
= Beck Depression Inventory; BAI = Beck Anxiety Inventory; SHAPS = Snaith-Hamilton Pleasure Scale; No. = 
number; % past ADM = percent of patients with previous history of antidepressant medication use (no patients were 
currently-medicated); % past PT = percent of patients with a previous history of psychological therapy (all patients 
were engaged in CBT during the trial); % baseline GAD=percent of patients who met criteria for generalised anxiety 
disorder (GAD) at baseline.  
 
 active tDCS sham tDCS 
N 20 19 
% female 45.00 57.89 
Age 35.60 (12.91) 31.05 (8.17) 
FSIQ 110.10 (7.49) 105.15 (7.54) 
Baseline HAM-D 21.95 (3.20) 21.05 (3.27) 
Baseline BDI 25.70 (8.01) 27.79 (5.34) 
Baseline SHAPS 19.85 (7.25) 18.05 (7.25) 
Baseline BAI 25.70 (13.57) 25.47 (12.06) 
Age of onset 22.80 (10.09) 18.37 (8.23) 
No. episodes 2.50 (1.67) 3.05 (1.58) 
% hospitalized 15.00 15.79 
% suicide attempt 30.00 21.05 
% past ADM 55.00 42.10 
% past PT 50.00 78.90 
% baseline GAD 75 68 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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Assessment of blinding and side effects  
 
38.5% of patients correctly guessed the stimulation condition, with no significant difference in 
the proportion of active and sham guesses between groups (X
2
=1.64, p=0.301), suggesting that 
blinding was effective. See Supplemental Materials details and full side-effects. 
 
Primary clinical outcome 
 
Using an intention-to-treat analysis (last observation carried forward), a greater proportion of 
patients responded (active: 50%; sham: 31.6%; odds ratio: 2.16, 95%CI=0.59—7.99) and 
remitted (active: 30%; sham: 10.5%; odds ratio: 3.65, 95%CI=0.63—20.96) following CBT with 
active than with sham tDCS (defined as a 50% or greater reduction on the Hamilton Rating Scale 
for Depression, HAM-D, and a HAM-D of less than 7, respectively). However, these differences 
did not achieve statistical significance (response: X
2
=1.37, p=0.24, φ=0.187; remission: X2=2.27, 
p=0.13, φ=0.241 (see Figure 2A). We repeated these analyses for the sample of patients who 
completed the trial (response: active: 52.6%; sham: 42.9%; odds ratio: 1.48; X
2
=0.308, p=0.579, 
φ=0.184; remission: active: 31.6%; sham: 14.3%; odds ratio: 2.76; X2=1.313, p=0.252, φ=0.090). 
 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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Fig 2. Effect of intervention on depressive symptoms and brain activation. A: Proportion of patients responding and 
remitting following CBT with active and sham tDCS. These differences did not achieve statistical significance. B: 
HAM-D scores reduced significantly from pre- to post-intervention, but the main effect of stimulation condition and 
the interaction were non-significant. C&D: Effect of intervention on neural activation during working memory 
(contrast: 3-back > 1-back). Activation in left (C) and right (D) dorsolateral prefrontal cortex (DLPFC) a priori 
regions-of-interest pre- and post-intervention (orange solid lines = active tDCS; green dotted lines = sham tDCS). E: 
Whole brain (WB) analysis of the effect of time (pre- versus post-intervention) and plotted eigenvariate of this main 
effect. E, left panel: we found significant changes in activation over time in bilateral DLPFC (increased over time: 
coronal section; p<0.001 (uncorrected) cluster-forming threshold, WB cluster-level FWE-corrected) and medial 
PFC/perigenual anterior cingulate cortex (decreased over time: sagittal and axial sections; p<0.001 (uncorrected) 
cluster-forming threshold, WB cluster-level FWE-corrected). E, right panel: for illustrative purposes, eigenvariate 
values extracted from the L-DLPFC cluster displayed in the left panel are plotted. F: WB effect of group (greater in 
active than sham tDCS condition) in the right posterior parietal cortex (rPPC) (p=0.02 WB voxel-level FWE 
corrected: F, left), and plotted eigenvariate of this rPPC cluster (F, right). Overlays are displayed at p<0.001 
(uncorrected) and colour bars indicate F-values. Error bars indicate standard errors of the mean. 
 
Secondary clinical outcomes 
 
HAM-D scores reduced significantly from pre- to post-intervention (F(1,37)=56.09, p<0.001, 
ηp
2
=0.603) (mean difference 9.30 (SD=6.82) in active, 6.68 (SD=6.49) in sham), but the main 
effect of stimulation condition (F(1,37)=0.112, p=0.739) and the stimulation-by-time interaction 
(F(1,37)=1.50, p=0.228) were non-significant (Figure 2B). The results were similar for 
completers (N=33). Including therapist as a covariate in this analysis produced similar results 
(see Supplemental Materials). There were no significant effects of stimulation condition on 
questionnaire measures or working memory performance (all p>0.1) (see Supplemental 
Materials for full results, and in-scanner task performance) 
Neural activation: n-back working memory task 
 
ROI analysis (a priori): Bilateral DLPFC activation increased after the intervention (main effect 
of time: F(1,31)=20.95, p<0.001, ηp
2
=0.403), but the interaction with group was non-significant 
(F(1,31)=0.363, p=0.551) (Figure 2). At baseline patients showed significantly lower bilateral 
DLPFC activation than 30 matched healthy controls (F(1,61)=8.24, p=0.006, ηp
2
=0.119), but 
there was no significant difference from healthy controls post-intervention (F(1,61)=0.191, 
p=0.664). There was no association between increased bilateral DLPFC activation and n-back 
improvement (r(33)=0.064, p=0.725). Full results in Supplemental Materials. 
 
Whole-brain analysis (exploratory): Activation increased significantly from pre- to post-
intervention in bilateral parietal cortex and bilateral DLPFC, and decreased significantly in 
medial prefrontal cortex, extending into perigenual ACC (all p<0.001, cluster-level FWE-
corrected; Figure 2E and Supplemental Table 2). Patients receiving active stimulation also had 
significantly greater activation in right posterior parietal cortex (rPPC) compared to sham 
(p=0.02 voxel-level FWE-corrected: Figure 2F). rPPC activation increased over time in the 
active condition (t(18)=2.96, p=0.008) but decreased numerically in the sham condition 
(t(13)=1.98, p=0.069) (group-by-time interaction: F(1,31)=11.74, p=0.002; Figure 2F). Note that 
since the contrast used to identify this result was the main effect of group, this group-by-time 
interaction is orthogonal, meaning this is not a circular analysis. 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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Neural activation: emotion processing task 
 
Amygdala ROI analysis (a priori): We found a significant time-by-simulation condition 
interaction in the amygdala (F(1,31)=5.04, p=0.032, ηp
2
=0.140): those in the sham group showed 
decreased amygdala activation (averaged across contrasts) at post- relative to pre-intervention 
(t(14)=2.63, p=0.021), while those in the active group did not (t(19)=0.605, p=0.553). 
Independent-samples t-tests revealed marginal (non-significant) differences between the active 
and sham conditions pre- (t(31)=1.74, p=0.092) and post-intervention (t(31)=1.96, p=0.059), 
such that there was numerically lower baseline amygdala activation and numerically higher post-
intervention amygdala activation in patients subsequently assigned to the active condition 
(compared to those assigned to sham). No other main or interaction effects reached significance 
(see Figure 3; full results described in Supplemental Materials). 
 
L-DLPFC ROI analysis (a priori): Similarly, there was a significant interaction between time 
and stimulation condition (F(1,31)=10.95, p=0.002, ηp
2
=0.261). In patients receiving active 
stimulation, left DLPFC activation (collapsing across fear and happy contrasts) marginally (non-
significantly) increased from pre-to post-intervention (t(18)=2.06, p=0.055); in patients receiving 
sham stimulation, left DLPFC activation decreased significantly (t(13)=2.62, p=0.021). 
Independent-samples t-tests revealed a marginal (non-significant) difference between the 
stimulation conditions at baseline (t(31)=1.88, p=0.07), but post-intervention there was 
significantly greater left DLPFC activation in the active compared to the sham stimulation group 
(t(31)=2.08, p=0.046). No other main or interaction effects reached significance (see 
Supplementary Materials). 
 
sgACC ROI analysis (a priori): There were no significant effects. 
 
Whole-brain analysis (exploratory): There were no significant main or interaction effects of 
stimulation condition on emotion processing at our corrected threshold of p=0.025 (cluster- or 
voxel-level) (see Supplemental Materials and Supplemental Table 3). 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
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Fig 3. Effect of intervention on neural activation during emotion processing. Activation in a priori regions of 
interest pre- and post-intervention (orange solid lines = active tDCS; green dotted lines = sham tDCS) for the fearful 
vs neutral (left column) and happy vs neutral (right column) contrasts: left amygdala (L Amyg, A-B); right 
amygdala (R Amyg, C-D); subgenual anterior cingulate cortex (sgACC, E-F); and left dorsolateral prefrontal cortex 
(L DLPFC, G-H). In the amygdalae (A-D) there was a significant time-by-stimulation condition interaction, with 
activation decreased from pre- to post-intervention in the sham condition only, with a similar pattern of results for 
fearful and happy stimuli. No significant effects were detected in the sgACC (E-F). In the left DLPFC (G-H), there 
was a similar time-by-stimulation condition interaction to that in the amygdala. 
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Prediction of outcome 
 
ROI analysis (a priori): In the L-DLPFC model (n-back: 3-back>1-back contrast), pre-treatment 
activation was significantly positively associated with subsequent percentage improvement in 
HAM-D score (F(1,29)=12.77, p=0.001, ηp
2
=0.306). There was also a significant interaction 
between activation and stimulation condition (F(1,29)=6.83, p=0.014, ηp
2
=0.191). This remained 
significant after controlling for baseline symptom and working memory scores (main effect: 
F(1,26)=29.90, p<0.001, ηp
2
=0.535); interaction: (F(1,26)=10.87, p=0.003, ηp
2
=0.295)) (see 
Supplemental Materials).  
 
Pre-treatment activation in L-DLPFC was significantly positively associated with subsequent 
symptomatic improvement in the active (r=0.711, p=0.001) but not sham (r=0.205, p=0.482) 
condition (Figure 4A). Note, n-back performance did not predict percentage improvement 
(r=0.112, p=0.536). Baseline L-DLPFC activation was not associated with baseline HAM-D 
severity (p>0.1). 
 
In the right amygdala model (emotion processing: fearful>neutral contrast), pre-treatment 
activation was significantly positively associated with subsequent percentage improvement in 
HAM-D score across both groups (F(1,29)=7.69, p=0.010, ηp
2
=0.210); the interaction with 
stimulation group was non-significant (F(1,29)=0.54, p=0.469) (Figure 4B).  
 
No other regions or their interaction with stimulation condition were significantly associated 
with clinical outcome (all p>0.1); therefore, we did not proceed with sensitivity or reliability 
analyses. 
 
Whole-brain analysis (exploratory): Higher pre-treatment activation in the left posterior parietal 
cortex during working memory (PPC, p=0.027, FWE cluster-corrected) and higher left rostral 
PFC during emotion processing (fearful>neutral contrast; p=0.001, FWE cluster-corrected) were 
positively associated with greater subsequent percentage improvement in HAM-D across both 
groups (Figure 4C-F); however, only the latter survived the Bonferroni corrected threshold of 
p=0.025 FWE. No interactions with stimulation group survived whole-brain correction for 
multiple comparisons (see Supplemental Tables 4-6).  
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Fig 4. ROI analysis: imaging biomarkers associated with clinical response. A: Clinical response (percentage 
reduction in HAM-D) was associated with greater pre-treatment left DLPFC activation during working memory (3-
back>1-back contrast) specifically in the active group (r=0.711, p=0.001) but not the sham group (r=0.205, 
p=0.482); interaction (F(1,29)=6.83, p=0.014). B: Clinical response was associated with greater pre-treatment right 
amygdala activation during emotion processing (fearful>neutral faces contrast) across both groups (F(1,29)=7.69, 
p=0.010). C: Results of whole-brain exploratory analysis for regions predictive of outcome in the n-back task (3-
back>1-back contrast) (p=0.027, cluster-corrected; note this does not fall below our stringent significance threshold 
of p=0.025). Crosshairs located at peak voxel in left posterior parietal cortex (L PPC). D: For illustrative purposes 
only, scatterplot of relationship between L PPC activation (eigenvariate of cluster) and percent reduction in 
Hamilton Depression Rating Scale (HAM-D) over the trial in active (orange solid line) and sham (teal dotted line) 
groups. E: Results of whole-brain exploratory analysis for regions predictive of outcome in the emotion processing 
task (fearful>neutral contrast) (p=0.001, cluster-corrected). Crosshairs located at peak voxel in left rostral prefrontal 
cortex (PFC); activation extends into bilateral OFC. F: For illustrative purposes only, scatterplot of relationship 
between left rostral PFC activation (eigenvariate of cluster) and percent reduction in Hamilton Depression Rating 
Scale (HAM-D) over the trial in active and sham groups. For 5D and F, note that responses were extracted from 
clusters identified through a voxelwise analysis and therefore the magnitude of the correlation will be inflated (and 
thus is shown for illustrative purposes only). 
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Post-hoc area-under-curve (AUC) analysis: L-DLPFC prediction of clinical response 
 
We repeated our primary analyses after dividing the sample into low and high L-DLPFC 
activation groups using a median split. Low L-DLPFC patients (N=19, 9 real; 10 sham) showed 
no difference between sham and real stimulation for either response (X
2
=0.540, p=0.463) or 
remission (X
2
=0.006, p=0.937). However, high L-DLPFC activation patients (N=20, 11 real; 9 
sham) were significantly more likely to respond to tDCS than sham stimulation (X
2
=5.69, 
p=0.017, φ=0.382; remission: X2=2.78, p=0.095, φ=0.267). A receiver operator characteristic 
analysis of the accuracy of predicting clinical response using baseline L-DLPFC activation 
revealed that the area-under-curve (AUC) for real stimulation was 0.856 (good) while for the 
sham group AUC=0.417 (no better than chance).   
 
Reliability  
 
Activation in the L-DLPFC ROI (3-back>1-back contrast) showed very good reliability between 
pre- and post-trial scans (combined ICC=0.67, 95%CI=0.33—0.84, p=0.001). This was the case 
for both active (ICC=0.69, 95%CI=0.19—0.88) and sham (ICC=0.65, 95%CI=-0.08—0.89) 
groups. However, activation in the R-amygdala ROI (fearful>neutral contrast) showed poor 
reliability between scans (combined ICC=-1.630, 95%CI=-4.325– -0.299, p=0.996; active: 
ICC=-1.83, 95%CI=-6.35– -0.09; sham: ICC=-1.26, 95%CI=-6.04– -0.27) (Supplemental Figure 
2). 
 
Discussion  
 
We conducted a mechanistic RCT of prefrontal tDCS combined with CBT for depression. We 
hypothesised that tDCS would enhance the therapeutic effect of CBT, compared with sham 
stimulation. Our results did not provide clear evidence for this; this may in part be due to the 
small sample size. On our mechanistic outcomes, we found that tDCS+CBT increased DLPFC 
activation relative to sham only during emotion processing, but not during working memory. 
Finally, we found a strong and specific association between pre-treatment L-DLPFC activation 
and subsequent clinical response, shedding light on the variability in our tDCS findings, and 
suggesting that it may be possible to identify which patients are most likely to respond to 
tDCS+CBT. 
 
We did not find clear evidence that tDCS enhances the efficacy of CBT. While it is possible that 
our trial was underpowered (we identified moderately-sized odds ratios between active and sham 
groups (response: 2.16; remission: 3.65)), we found no effect of tDCS self-reported depressive 
symptoms. Thus, the clinical relevance of tDCS combined with CBT remains to be determined in 
future, larger studies. It is also possible that the intervention itself is not clinically efficacious on 
average because of inter-individual variability in response to tDCS. Indeed, a recent large-scale 
international trial of tDCS for depression reported a null result (the trial used a more typical daily 
or near-daily administration schedule, and a higher dosage)[17]. Therefore, one of the most 
important aspects of our trial was its mechanistic measures, which we could use to begin to 
explore such variability.  
 
©    2019 American College of Neuropsychopharmacology. All rights reserved.
18 
 
This trial was unusual in its inclusion of fMRI measurements. This design is central to 
understanding the possible mechanisms of tDCS+CBT, and can also illuminate sources of inter-
individual variability. Here, DLPFC activation during working memory increased substantially 
over the trial (irrespective of condition), consistent with a smaller study[39], to a level 
comparable with healthy volunteers. Additionally, specifically under active tDCS, right PPC 
activation increased from pre- to post-intervention. This might reflect long-range effects of tDCS 
on the parietal cortex[9], which is robustly activated by the n-back task[40]. Similarly, L-DLPFC 
and bilateral amygdala activation during emotion processing generally decreased over time under 
sham stimulation, but increased under active stimulation. Thus, although DLPFC activation 
during working memory did not increase more during active than during sham stimulation, we 
did show treatment-dependent effects on the DLPFC during emotion processing.  
 
Most importantly, we found that greater L-DLPFC activation prior to treatment was associated 
with greater subsequent symptomatic improvement, consistent with results from a small rTMS 
study[30]. Critically, this was only the case in patients receiving active stimulation, and this 
measure showed good reliability, a marker of potential utility as an fMRI ―biomarker‖[41]. 
Additionally, pre-treatment responses in the PPC (during working memory) and rostral PFC and 
right amygdala (during emotion processing) were associated with subsequent response to CBT, 
irrespective of stimulation condition (although note that the PPC result marginally missed 
statistical significance at our stringent FWE-corrected level of p=0.025). The amygdala result 
replicates the results of two previous neuroimaging investigations of CBT response[39,42], 
although puzzlingly the right amygdala also shows extremely poor test-retest reliability[41].  
 
Our results suggest the DLPFC may have potential in predicting response to neurostimulation in 
depression, a result confirmed by significant effects on our primary outcome (HAM-D response) 
for the high-L-DLPFC group only, and by high accuracy of an ROC analysis using baseline L-
DLPFC activation. In contrast, n-back working memory performance was not associated with 
improved clinical response. The high within-subject reliability of L-DLPFC activation fulfils a 
vital criterion for a clinically useful predictor, and suggests L-DLPFC BOLD response is more 
stable than other regions proposed as ‗biomarkers‘, such as the sgACC and amygdala, which 
appear to have poor within-subject reliability[41], a finding we replicated here.  
 
Individual differences in baseline DLPFC activation may contribute to the notable 
inconsistencies in the broader field of prefrontal tDCS[23]. Speculatively, while clinical response 
to our low dose of tDCS (1mA) is associated with high L-DLPFC activation at baseline, other 
dosages (for instance, the 2.5 mA used in a recent negative international clinical trial[17]) might 
show a different, or even reversed, relationship with DLPFC activation, making incorporation of 
mechanistic measures in future trials essential. 
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Limitations and future directions 
 
Despite the strengths of our mechanistic design, there are important limitations, including 
relatively weak current strength and a fronto-extracephalic electrode montage. This montage 
results in comparatively diffuse frontal stimulation according to current flow models[33]. We 
chose this montage because in a preliminary open-label study, it was substantially more effective 
for depression than a bifrontal tDCS montage[34]. We have previously shown an identical 
montage and current strength to have cognitive effects in healthy controls[43]. Recent work has 
confirmed the physiological validity of unilateral 1mA montages, failing to show physiological 
validity for bilateral stimulation or 2mA intensity conditions[35], despite their efficacy in 
previous depression trials[12,44]. It also bears mentioning that we found increased redness and 
itching observed in the real versus sham conditions; however, patients were worse than chance at 
guessing their stimulation condition (other side-effects were significantly more common in the 
sham condition).  
 
Our weekly stimulation schedule could also have contributed to our null clinical result[11–14] 
(weekly CBT sessions is typical for NHS outpatients with moderate-to-severe depression). 
Furthermore, there is inherent heterogeneity between CBT therapists (confirmed here, despite 
efforts to standardise treatment); although including therapist as a covariate did not change our 
analyses.  
 
Finally, we discovered a potential predictor of treatment outcome (baseline L-DLPFC 
activation), but it is as-yet unclear how this potential predictor relates to cognitive factors; 
importantly, baseline working memory was not predictive of treatment outcome. It is possible 
that DLPFC activation during the n-back task is reflective of a more general cold cognitive 
capacity than working memory ability per se; other cognitive measures of executive function (or 
perhaps a combined measure) may be better predictors of outcome than the n-back. One of the 
most important factors to establish, if tDCS is an effective intervention for depression, is the 
particular neural target it engages. While the most intuitive candidate is the region stimulated, 
our result failed to show any differential treatment effects on this region. Instead, we found a 
general increase in bilateral DLPFC activation regardless of tDCS condition. Future work should 
explore the contribution of baseline variables to this change in DLPFC activation. However, it is 
certainly possible that while the immediate neural effects of tDCS occur within the stimulated 
region (as previous work would suggest[45]), the longer-term mechanisms driving its clinical 
effect may be more distally located (for example, in the parietal cortex, as suggested by our 
exploratory whole-brain analysis). 
Conclusion 
 
Our data do not provide clear support for the use of tDCS to augment CBT in depression in all 
patients, but we discovered a biomarker explaining variability in tDCS response: baseline 
activation in the area of stimulation (L-DLPFC). This biomarker appears relatively strong and 
specific to active stimulation. Our data speak to the potential utility of neuroscience techniques 
in developing novel mental health interventions; incorporating cognitive neuroscience measures 
into clinical trials could allow simultaneous assessment of clinical efficacy and detection of 
potential biomarkers of treatment response. Ultimately, these data could guide patient selection 
in larger clinical trials, and, if confirmed, inform clinical use of tDCS in depression.   
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Figure legends 
 
Fig 1. CONSORT diagram describing recruitment, randomization, and attrition in the clinical 
trial (A) and depiction of trial procedure (B). CBT=cognitive behavioural therapy; 
tDCS=transcranial direct current stimulation; HAM-D=Hamilton Rating Scale for Depression; 
fMRI=functional magnetic resonance imaging. 
 
Fig 2. Effect of intervention on depressive symptoms and brain activation. A: Proportion of 
patients responding and remitting following CBT with active and sham tDCS. These differences 
did not achieve statistical significance. B: HAM-D scores reduced significantly from pre- to 
post-intervention, but the main effect of stimulation condition and the interaction were non-
significant. C&D: Effect of intervention on neural activation during working memory 
(contrast: 3-back > 1-back). Activation in left (C) and right (D) dorsolateral prefrontal cortex 
(DLPFC) a priori regions-of-interest pre- and post-intervention (orange solid lines = active 
tDCS; green dotted lines = sham tDCS). E: Whole brain (WB) analysis of the effect of time (pre- 
versus post-intervention) and plotted eigenvariate of this main effect. E, left panel: we found 
significant changes in activation over time in bilateral DLPFC (increased over time: coronal 
section; p<0.001 (uncorrected) cluster-forming threshold, WB cluster-level FWE-corrected) and 
medial PFC/perigenual anterior cingulate cortex (decreased over time: sagittal and axial sections; 
p<0.001 (uncorrected) cluster-forming threshold, WB cluster-level FWE-corrected). E, right 
panel: for illustrative purposes, eigenvariate values extracted from the L-DLPFC cluster 
displayed in the left panel are plotted. F: WB effect of group (greater in active than sham tDCS 
condition) in the right posterior parietal cortex (rPPC) (p=0.02 WB voxel-level FWE corrected: 
F, left), and plotted eigenvariate of this rPPC cluster (F, right). Overlays are displayed at p<0.001 
(uncorrected) and colour bars indicate F-values. Error bars indicate standard errors of the mean. 
 
Fig 3. Effect of intervention on neural activation during emotion processing. Activation in a 
priori regions of interest pre- and post-intervention (orange solid lines = active tDCS; green 
dotted lines = sham tDCS) for the fearful vs neutral (left column) and happy vs neutral (right 
column) contrasts: left amygdala (L Amyg, A-B); right amygdala (R Amyg, C-D); subgenual 
anterior cingulate cortex (sgACC, E-F); and left dorsolateral prefrontal cortex (L DLPFC, G-H). 
In the amygdalae (A-D) there was a significant time-by-stimulation condition interaction, with 
activation decreased from pre- to post-intervention in the sham condition only, with a similar 
pattern of results for fearful and happy stimuli. No significant effects were detected in the 
sgACC (E-F). In the left DLPFC (G-H), there was a similar time-by-stimulation condition 
interaction to that in the amygdala. 
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Fig 4. ROI analysis: imaging biomarkers associated with clinical response. A: Clinical response 
(percentage reduction in HAM-D) was associated with greater pre-treatment left DLPFC 
activation during working memory (3-back>1-back contrast) specifically in the active group 
(r=0.711, p=0.001) but not the sham group (r=0.205, p=0.482); interaction (F(1,29)=6.83, 
p=0.014). B: Clinical response was associated with greater pre-treatment right amygdala 
activation during emotion processing (fearful>neutral faces contrast) across both groups 
(F(1,29)=7.69, p=0.010). C: Results of whole-brain exploratory analysis for regions predictive of 
outcome in the n-back task (3-back>1-back contrast) (p=0.027, cluster-corrected; note this does 
not fall below our stringent significance threshold of p=0.025). Crosshairs located at peak voxel 
in left posterior parietal cortex (L PPC). D: For illustrative purposes only, scatterplot of 
relationship between L PPC activation (eigenvariate of cluster) and percent reduction in 
Hamilton Depression Rating Scale (HAM-D) over the trial in active (orange solid line) and sham 
(teal dotted line) groups. E: Results of whole-brain exploratory analysis for regions predictive of 
outcome in the emotion processing task (fearful>neutral contrast) (p=0.001, cluster-corrected). 
Crosshairs located at peak voxel in left rostral prefrontal cortex (PFC); activation extends into 
bilateral OFC. F: For illustrative purposes only, scatterplot of relationship between left rostral 
PFC activation (eigenvariate of cluster) and percent reduction in Hamilton Depression Rating 
Scale (HAM-D) over the trial in active and sham groups. For 5D and F, note that responses were 
extracted from clusters identified through a voxelwise analysis and therefore the magnitude of 
the correlation will be inflated (and thus is shown for illustrative purposes only). 
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